• Publications
  • Influence
Depression and Parkinson’s disease
Abstract.Depression occurs in approximately 45% of all patients with Parkinson’s disease (PD), reduces quality of life independent of motor symptoms and seems to be underrated and undertreated.Expand
  • 165
  • 8
Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration
Although some reports on neurostimulation are positive, no effective treatment method for camptocormia in Parkinson's disease (PD) is known to date. We aim to identify prognostic factors for aExpand
  • 36
  • 4
Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences
Background and objective The extent to which deep brain stimulation (DBS) can improve quality of life may be perceived as a permanent trade-off between neurological improvements and complications ofExpand
  • 44
  • 4
  • PDF
Monoamine transporter availability in Parkinson’s disease patients with or without depression
PurposeDepression is a common symptom in patients suffering from Parkinson’s disease (PD) and markedly reduces their quality of life. As post-mortem studies have shown, its presence may reflectExpand
  • 64
  • 3
Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease
The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of l-amphetamine and l-methamphetamine in plasma is safe and wellExpand
  • 23
  • 2
Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach
BACKGROUND Dopamine-D2 receptor imaging with single-photon emission computed tomography (SPECT) and [(123)I]IBZM is of great interest for basic and applied neurosciences. However, the use of kineticExpand
  • 18
  • 2
Efficacy and safety of high‐dose cabergoline in Parkinson's disease
Objectives –  To assess the efficacy and safety of high‐dose (up to 20 mg/day) cabergoline in Parkinson's disease (PD) patients with motor fluctuations and/or dyskinesias.
  • 19
  • 1
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypicalExpand
  • 16
  • 1
Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD): An 11-Week Randomized Comparison Trial Against
Objectives The aim of this study was to investigate the effects of piribedil on vigilance and cognitive performance in patients with Parkinson disease experiencing excessive daytime sleepiness onExpand
  • 16
  • 1